[Stent therapy with diabetic patients who have coronary artery disease]

W Motz1, R Kaiser

  • 1Klinikum Karlsburg, Herz- u. Diabeteszentrum Mecklenburg-Vorpommern, Greifswalder Strasse 11, 17495 Karlsburg, Germany.

Insights

Diabetic patients with coronary artery disease fare better with drug-eluting stents compared to bare-metal stents, eliminating the previous poorer prognosis. This improved outcome applies even to high-risk patients with in-stent stenosis.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Context:

  • Diabetic patients with coronary artery disease (CAD) historically exhibit poorer outcomes post-coronary intervention with bare-metal stents (BMS).
  • This disparity highlights a significant challenge in managing cardiovascular health for diabetic populations.
  • Drug-eluting stents (DES) have emerged as a potential solution to mitigate these risks.

Purpose:

  • To evaluate the efficacy of drug-eluting stents (DES) in improving outcomes for diabetic patients undergoing coronary interventions.
  • To compare the prognosis of diabetic versus non-diabetic patients treated with DES versus BMS.
  • To assess the effectiveness of DES in managing complex cases, including in-stent restenosis.

Summary:

  • Clinical studies demonstrate that the use of drug-eluting stents (sirolimus-eluting stent [Cypher] and paclitaxel-eluting stent [Taxus]) negates the poorer prognosis previously observed in diabetic patients with CAD treated with bare-metal stents.
  • Drug-eluting stents provide an effective treatment option for diabetic patients, normalizing their outcomes compared to non-diabetic individuals.
  • These stents are also highly effective in treating high-risk patient groups, such as those with in-stent stenosis.

Impact:

  • Drug-eluting stents significantly improve the prognosis for diabetic patients with coronary artery disease, reducing disparities in treatment outcomes.
  • The findings support the expanded use of drug-eluting stents in diabetic populations to achieve outcomes comparable to non-diabetic patients.
  • This advancement offers a more effective therapeutic strategy for managing coronary artery disease and in-stent restenosis in diabetic individuals.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...